Laurus Labs quarterly results

Q2 FY27 · Jul–Sep 2026

₹ crore	Q2 FY27	Q2 FY26	Change
Revenue	2,206	1,653	+33.4%
EBITDA	750	403	+86.1%
EBITDA margin	34.0%	24.4%	+9.6 pts
Profit before tax	592	270	+119.4%
Net profit	436	194	+124.3%
EPS	₹8.17	₹3.61	+126.3%

Every quarter

₹ crore except per share

Tap a line for its trend	Q2 FY27Sep 2026	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Earlier quartersAlpha Plus

Expenses
	2,206	2,026	1,812	1,778	1,653	1,570	1,720	1,415	1,224	1,195	1,440	1,195	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	13.0	9.2	11.8	5.8	27.0	10.4	58.6	9.4	4.6	2.5	18.5	2.4
	2,219	2,035	1,823	1,784	1,680	1,580	1,779	1,424	1,228	1,197	1,458	1,197
	901	786	793	725	677	599	626	653	577	572	591	634
	45.0	35.1	48.2	55.1	30.7	38.5	22.3	34.8	25.6	22.7	40.8	17.5
	−130	−64.9	−141	−85.9	−44.0	−0.6	134	−77.6	−54.5	−57.9	89.8	−106
	266	259	236	229	216	215	178	189	179	174	161	155
	44.1	42.2	40.4	38.8	40.0	51.5	56.4	57.8	52.6	49.2	50.5	50.8
	127	124	122	121	120	117	110	106	108	106	102	98.4
	374	373	364	374	371	335	339	331	318	313	315	313
	1,628	1,554	1,462	1,457	1,411	1,356	1,467	1,294	1,205	1,179	1,351	1,163
	750	638	512	480	403	382	421	285	178	171	241	181
	623	514	390	360	283	265	310	179	70.8	65.1	139	83.0
Profit
	592	481	361	327	270	224	312	131	22.8	18.5	107	34.6
	592	481	361	327	270	224	312	131	22.8	18.5	107	34.6
	163	135	78.1	71.5	87.9	60.0	80.3	35.0	23.2	18.4	43.4	18.4
	−7.9	−15.5	1.3	2.0	−11.9	3.1	−1.9	5.1	−18.1	−12.2	−11.4	−9.0
	155	119	79.5	73.5	76.0	63.1	78.5	40.1	5.1	6.3	32.0	9.5
	−0.6	0.1	0.2	−1.2	0.7	0.6	−1.1	2.3	2.2	0.5	−0.3	−1.8
	436	362	282	252	194	162	233	92.9	20.0	12.7	75.0	23.3
	437	362	282	253	194	161	234	90.6	17.7	12.2	75.3	25.2
	−2.3	−2.2	2.1	−1.6	−5.7	−0.7	−2.1	−1.5	−0.4	0.3	2.3	−1.1
	434	360	284	250	189	161	231	91.5	19.5	13.0	77.3	22.3
	441	368	279	252	195	163	234	92.3	19.8	12.5	75.6	23.1
	−5.3	−5.5	3.0	0.2	−0.5	−1.3	−0.9	0.6	0.1	0.2	−0.6	0.2
Per share
	₹8.17	₹6.81	₹5.17	₹4.67	₹3.61	₹3.02	₹4.34	₹1.71	₹0.37	₹0.23	₹1.40	₹0.43
	₹8.16	₹6.80	₹5.17	₹4.65	₹3.61	₹3.02	₹4.33	₹1.71	₹0.37	₹0.23	₹1.40	₹0.43
Other comprehensive income — detail
	−2.3	−2.2	2.1	−1.6	−5.7	−0.7	−2.1	—	—	—	—	—
	−2.4	−2.4	5.0	−1.7	−0.2	−0.3	−2.2	0.3	0.3	0.4	3.7	−1.6
	−0.6	−0.6	0.0	0.0	0.0	−0.1	0.0	—	—	—	—	—
	—	—	—	—	—	—	—	0.0	0.0	0.1	0.9	−0.4
	−0.5	−0.4	−2.9	0.1	−5.5	−0.5	0.2	−1.8	−0.7	0.0	−0.5	—
	—	—	—	—	—	—	—	0.0	0.0	0.0	0.0	−0.2
	439	365	281	250	189	162	232	90.8	19.4	12.8	77.9	22.1
	−5.3	−5.5	2.9	0.2	−0.5	−1.3	−0.9	0.6	0.1	0.2	−0.6	0.2
Per share — as-filed variants
	₹8.17	₹6.81	₹5.17	₹4.67	₹3.61	₹3.02	₹4.34	₹1.71	₹0.37	₹0.23	₹1.40	₹0.43
	₹8.16	₹6.80	₹5.17	₹4.65	₹3.61	₹3.02	₹4.33	₹1.71	₹0.37	₹0.23	₹1.40	₹0.43
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	1,390	1,270	1,111	1,084	990	932	938	805	675	658	718	650
	63.0%	62.7%	61.4%	60.9%	59.9%	59.4%	54.5%	56.9%	55.2%	55.1%	49.8%	54.4%
Adjusted (ex-exceptional items) — derived
	592	481	361	327	270	224	312	131	22.8	18.5	107	34.6
	436	362	282	252	194	162	233	92.9	20.0	12.7	75.0	23.3
	₹8.17	₹6.81	₹5.17	₹4.67	₹3.61	₹3.02	₹4.34	₹1.71	₹0.37	₹0.23	₹1.40	₹0.43

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

LAURUSLABS₹2,181.90

Laurus Labs Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersDIVISLAB GLAND MANKIND BIOCON ALKEM LUPIN FORTIS GLENMARKMcap ₹1.18L Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026	Q2 FY27 30/09/2026
Revenue from Operations	1,194.9	1,439.7	1,194.9	1,223.7	1,415.1	1,720.3	1,569.6	1,653.5	1,778.3	1,811.6	2,026.3	2,206.4
Other Income	2.4	18.5	2.5	4.6	9.4	58.6	10.4	27.0	5.8	11.8	9.2	13.0
Total Income	1,197.4	1,458.2	1,197.4	1,228.3	1,424.5	1,778.9	1,580.0	1,680.4	1,784.1	1,823.4	2,035.5	2,219.4
Expenses
+ Cost of Materials Consumed	634.1	591.4	572.1	577.2	653.0	626.3	599.4	676.8	725.3	792.9	785.8	900.7
+ Purchases of Stock-in-Trade	17.5	40.8	22.7	25.6	34.8	22.3	38.5	30.7	55.1	48.2	35.1	45.0
+ Changes in Inventories	-106.3	89.8	-57.9	-54.5	-77.6	134.0	-0.6	-44.0	-85.9	-141.0	-64.9	-129.6
+ Employee Benefit Expense	155.0	161.1	174.0	178.7	189.1	177.7	214.8	215.6	229.2	235.9	258.7	265.7
+ Finance Costs	50.8	50.5	49.2	52.6	57.8	56.4	51.5	40.0	38.8	40.4	42.2	44.1
+ Depreciation & Amortisation	98.4	102.3	106.1	107.5	106.1	110.4	116.8	120.5	120.6	122.1	123.9	127.4
+ Other Expenses	313.1	315.1	312.9	318.4	330.6	339.3	335.3	371.2	374.3	363.5	373.3	374.3
Total Expenses	1,162.7	1,350.9	1,179.0	1,205.5	1,293.8	1,466.5	1,355.8	1,410.7	1,457.5	1,462.0	1,554.1	1,627.6
EBITDA	181.4	241.5	171.2	178.3	285.2	420.6	382.1	403.3	480.2	512.1	638.3	750.3
EBIT	83.0	139.2	65.1	70.8	179.1	310.2	265.3	282.8	359.6	390.0	514.4	622.9
Profit
PBT before Exceptional Items	34.6	107.3	18.5	22.8	130.7	312.3	224.2	269.7	326.6	361.4	481.4	591.8
Pretax Income	34.6	107.3	18.5	22.8	130.7	312.3	224.2	269.7	326.6	361.4	481.4	591.8
+ Current Tax	18.4	43.4	18.4	23.2	35.0	80.3	60.0	87.9	71.5	78.1	134.9	162.9
+ Deferred Tax	-9.0	-11.4	-12.2	-18.1	5.1	-1.9	3.1	-11.9	2.0	1.3	-15.5	-7.9
Tax Expense	9.5	32.0	6.3	5.1	40.1	78.5	63.1	76.0	73.5	79.5	119.4	155.1
+ Share of Associates & JVs	-1.8	-0.3	0.5	2.2	2.3	-1.1	0.6	0.7	-1.2	0.2	0.1	-0.6
Net Income	23.3	75.0	12.7	20.0	92.9	232.8	161.7	194.5	251.9	282.1	362.1	436.2
+ Net Income — Continuing Ops	25.2	75.3	12.2	17.7	90.6	233.9	161.1	193.8	253.1	281.9	362.0	436.7
+ Other Comprehensive Income	-1.1	2.3	0.3	-0.4	-1.5	-2.1	-0.7	-5.7	-1.6	2.1	-2.2	-2.3
Total Comprehensive Income	22.3	77.3	13.0	19.5	91.5	230.7	161.0	188.8	250.3	284.2	359.9	433.9
Net Income to Common	23.1	75.6	12.5	19.8	92.3	233.7	163.0	195.0	251.7	279.1	367.6	441.5
Minority Interest	0.2	-0.6	0.2	0.1	0.6	-0.9	-1.3	-0.5	0.2	3.0	-5.5	-5.3
Per Share
Basic EPS	0.43	1.40	0.23	0.37	1.71	4.34	3.02	3.61	4.67	5.17	6.81	8.17
Diluted EPS	0.43	1.40	0.23	0.37	1.71	4.33	3.02	3.61	4.65	5.17	6.80	8.16
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	-2.1	-0.7	-5.7	-1.6	2.1	-2.2	-2.3
+ Items NOT to be Reclassified to P&L	-1.6	3.7	0.4	0.3	0.3	-2.2	-0.3	-0.2	-1.7	5.0	-2.4	-2.4
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	0.0	-0.1	0.0	0.0	0.0	-0.6	-0.6
+ Tax on Items NOT to be Reclassified — alt tag	-0.4	0.9	0.1	0.0	0.0	—	—	—	—	—	—	—
+ Items to be Reclassified to P&L	—	-0.5	0.0	-0.7	-1.8	0.2	-0.5	-5.5	0.1	-2.9	-0.4	-0.5
+ Tax on Items to be Reclassified — alt tag	-0.2	0.0	0.0	0.0	0.0	—	—	—	—	—	—	—
Comprehensive Income — Owners of Parent	22.1	77.9	12.8	19.4	90.8	231.6	162.3	189.3	250.1	281.2	365.4	439.1
Comprehensive Income — Non-controlling Interests	0.2	-0.6	0.2	0.1	0.6	-0.9	-1.3	-0.5	0.2	2.9	-5.5	-5.3
Per Share — as-filed variants
Basic EPS — Continuing Operations	0.43	1.40	0.23	0.37	1.71	4.34	3.02	3.61	4.67	5.17	6.81	8.17
Diluted EPS — Continuing Operations	0.43	1.40	0.23	0.37	1.71	4.33	3.02	3.61	4.65	5.17	6.80	8.16
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	649.5	717.7	658.1	675.4	804.9	937.6	932.2	990.0	1,083.7	1,111.5	1,270.3	1,390.3
Gross Margin %	54.36	49.85	55.07	55.19	56.88	54.50	59.39	59.88	60.94	61.35	62.69	63.01
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	34.6	107.3	18.5	22.8	130.7	312.3	224.2	269.7	326.6	361.4	481.4	591.8
Net Income Adj (tax-effected)	23.3	75.0	12.7	20.0	92.9	232.8	161.7	194.5	251.9	282.1	362.1	436.2
EPS Adj	0.43	1.40	0.23	0.37	1.71	4.34	3.02	3.61	4.67	5.17	6.81	8.17
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
Paid Up Equity Capital	107.8	107.8	107.8	107.8	107.9	107.9	108.0	108.0	108.0	108.0	108.1	108.1

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q2 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Laurus Labs Q2 FY27 results (July–September 2026)

Filed with NSE on Thursday, 29 October 2026 at 2:55 pm IST

Laurus Labs (NSE: LAURUSLABS) reported its Q2 FY27 results (July–September 2026) on Thursday, 29 October 2026 at 2:55 pm IST. Consolidated net profit attributable to shareholders was ₹441 crore, up 126.4% from ₹195 crore in Q2 FY26 and up 20.1% from ₹368 crore in Q1 FY27. Revenue from operations was ₹2,206 crore, up 33.4% year on year and up 8.9% from the previous quarter.

Q2 FY26 results (a year earlier): 23 October 2025
Q3 FY27 results due by: 14 February 2027

Q2 FY27 at a glance · consolidated

Net profit (shareholders'): ₹441 Cr+126.4% vs Q2 FY26+20.1% vs Q1 FY27Total incl. minority interest ₹436 Cr
Revenue from operations: ₹2,206 Cr+33.4% vs Q2 FY26+8.9% vs Q1 FY27
Operating margin (EBIT): 28.2%+11.1 pts vs Q2 FY26+2.8 pts vs Q1 FY27EBIT ₹623 Cr
EBITDA: ₹750 Cr+86.1% vs Q2 FY26+17.6% vs Q1 FY27margin 34.0%
Earnings per share (basic): ₹8.17+126.3% vs Q2 FY26+20.0% vs Q1 FY27
Net profit margin: 20.0%+8.2 pts vs Q2 FY26+1.9 pts vs Q1 FY27

Questions

What was Laurus Labs' net profit in Q2 FY27?

Consolidated net profit attributable to shareholders was ₹441 crore, up 126.4% from ₹195 crore in Q2 FY26 and up 20.1% from ₹368 crore in Q1 FY27. Including the minority shareholders' share, total profit was ₹436 crore.

How were Laurus Labs' Q2 FY27 results?

Both grew from a year earlier: net profit was up 126.4% at ₹441 crore and revenue was up 33.4% at ₹2,206 crore. The operating margin was 28.2%, up 11.1 percentage points from 17.1% a year earlier. Against Q1 FY27, net profit was up 20.1% and revenue up 8.9%.

What is Laurus Labs' net profit margin?

Laurus Labs' net profit margin was 20.0% in Q2 FY27 (net profit attributable to shareholders as a share of revenue from operations), against 11.8% in Q2 FY26 (up 8.2 percentage points). For FY26 as a whole it was 13.0%.

What was Laurus Labs' revenue in Q2 FY27?

Revenue from operations was ₹2,206 crore, up 33.4% year on year and up 8.9% from the previous quarter.

What was Laurus Labs' EPS in Q2 FY27?

Basic earnings per share were ₹8.17, against ₹3.61 in Q2 FY26.

What was Laurus Labs' revenue in FY26?

Revenue from operations was ₹6,813 crore in FY26 (April 2025–March 2026), up 22.7% from ₹5,554 crore in FY25. It was ₹5,041 crore in FY24 and ₹6,041 crore in FY23: up 12.8% over three years, 4.1% a year on average.

What was Laurus Labs' operating margin in Q2 FY27?

Operating profit (EBIT — revenue less operating expenses, before finance costs and other income) was ₹623 crore, a margin of 28.2%, against 25.4% in Q1 FY27 and 17.1% in Q2 FY26. EBITDA was ₹750 crore, 34.0% of revenue.

What was Laurus Labs' net profit in the first half of FY27?

Consolidated net profit attributable to shareholders for the first half of FY27 (April–September 2026) was ₹809 crore, up 126.0% from ₹358 crore in the same months a year earlier. Revenue from operations was ₹4,233 crore, up 31.3%.

What was Laurus Labs' net profit in FY26?

Consolidated net profit attributable to shareholders was ₹889 crore in FY26 (April 2025–March 2026), up 148.0% from ₹358 crore in FY25. It was ₹161 crore in FY24 and ₹790 crore in FY23: up 12.5% over three years, 4.0% a year on average.

How has Laurus Labs' profit changed over the last four quarters?

Net profit attributable to shareholders by quarter: ₹252 crore in Q3 FY26, ₹279 crore in Q4 FY26, ₹368 crore in Q1 FY27 and ₹441 crore in Q2 FY27. That is ₹1,340 crore over the four quarters, up 95.9% from ₹684 crore in the four quarters before. Revenue from operations: ₹1,778 crore, ₹1,812 crore, ₹2,026 crore and ₹2,206 crore.

When did Laurus Labs announce its Q2 FY27 results?

On Thursday, 29 October 2026 at 2:55 pm IST, in its results filing to the stock exchanges. A year earlier it reported Q2 FY26 on 23 October 2025.

When will Laurus Labs announce its Q3 FY27 results?

Q3 FY27 covers October–December 2026. Listed companies must publish quarterly results within 45 days of the quarter's end (SEBI listing rules, Regulation 33), so the results are due by 14 February 2027. The company tells the exchanges the date of the board meeting at least two working days before it.

Where do these Laurus Labs figures come from?

From Laurus Labs' own consolidated results filings to NSE, in ₹ crore as filed (Q2 FY27 on 29 October 2026). Growth compares the same consolidated figures a year and a quarter earlier.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.